Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

05 mars 2014 08h30 HE | Source: Zogenix

Zogenix Reports Granting of Inducement Awards

SAN DIEGO, March 5, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
27 févr. 2014 16h30 HE | Source: Zogenix

Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2013 Financial Results

SAN DIEGO, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
13 févr. 2014 08h30 HE | Source: Zogenix

Data From Zohydro(TM) ER (hydrocodone bitartrate) Phase 3 Clinical Trial Published in Pain Medicine Demonstrates Its Benefit as a Therapeutic Option for the Management of Pain Severe Enough to Require Daily, Around-the-Clock, Long-Term Opioid Treatment and for Which Alternative Treatment Options Are Inadequate

SAN DIEGO, Feb. 13, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
12 févr. 2014 13h59 HE | Source: Zogenix

Zogenix Establishes External Safe-Use Board

SAN DIEGO, Feb. 12, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system...
11 févr. 2014 08h30 HE | Source: Zogenix

Zogenix Provides Update on Zohydro(TM) ER (hydrocodone bitartrate) Launch Readiness Plans

SAN DIEGO, Feb. 11, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
04 févr. 2014 08h00 HE | Source: Zogenix

Zogenix to Present at Leerink Swann 2014 Global Healthcare Conference

SAN DIEGO, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
04 févr. 2014 07h30 HE | Source: Zogenix

Zogenix Reports Granting of Inducement Awards

SAN DIEGO, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
13 janv. 2014 08h30 HE | Source: Zogenix

Zogenix Announces Preliminary Fourth Quarter 2013 Gross Product Sales

SAN DIEGO, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
09 janv. 2014 08h30 HE | Source: Zogenix

Zogenix and Mallinckrodt Agree to End Co-Promotion for SUMAVEL(R) DosePro(R) Effective January 31, 2014

SAN DIEGO, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
07 janv. 2014 07h30 HE | Source: Zogenix

Zogenix Reports Granting of Inducement Awards

SAN DIEGO, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...

Page précédente

Page suivante